[HTML][HTML] Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a …
HH Hsieh, TY Wu, CH Chen, YH Kuo, MJ Hour - BMC cancer, 2023 - Springer
Background This retrospective cohort study examined the impact of tetracyclines (TCs) and
proton pump inhibitors (PPIs) alone or in combination on the efficacy of epidermal growth …
proton pump inhibitors (PPIs) alone or in combination on the efficacy of epidermal growth …
[HTML][HTML] Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
CH Lee, MC Shen, MJ Tsai, JS Chang, YB Huang… - Scientific Reports, 2022 - nature.com
Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …
[HTML][HTML] Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor‑targeted therapy in advanced non‑small cell lung cancer
K Liu, W Zhang, Q Tan, G Jiang… - Oncology Letters, 2019 - spandidos-publications.com
Non‑small cell lung cancer (NSCLC) is closely associated with inflammation and chronic
infection. Antibiotics are frequently prescribed for NSCLC patients in combination with …
infection. Antibiotics are frequently prescribed for NSCLC patients in combination with …
Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs …
Z Li, H Guo, Y Lu, J Hu, H Luo, W Gu - OncoTargets and therapy, 2018 - Taylor & Francis
Purpose The development of acquired resistance to the first-line epidermal growth factor-
tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC) is …
tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC) is …
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
SJ Lee, JM Sun, SH Lee, JS Ahn, K Park, MJ Ahn - Lung Cancer, 2015 - Elsevier
Objectives After failure of first-line epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR TKIs) in patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating …
(EGFR TKIs) in patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating …
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review
XW Yang, K Yang, KY Kuang - Current oncology reports, 2014 - Springer
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been
extensively investigated in previously treated advanced non-small-cell lung cancer …
extensively investigated in previously treated advanced non-small-cell lung cancer …
Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment-a nationwide population-based study
YH Fang, YH Yang, MJ Hsieh, MS Hung… - Cancer management …, 2019 - Taylor & Francis
Purpose Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentration
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …
[HTML][HTML] Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of …
M Zhang, H Guo, S Zhao, Y Wang, M Yang, J Yu… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The role of a combination of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) and chemotherapy for non-small-cell lung cancer (NSCLC) has not been well …
(EGFR-TKIs) and chemotherapy for non-small-cell lung cancer (NSCLC) has not been well …
[HTML][HTML] Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non …
W Sim, SR Jain, WH Lim, YH Chin, CH Ng… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
increasingly used for advanced non-small cell lung cancer (NSCLC) as first-line therapy …
increasingly used for advanced non-small cell lung cancer (NSCLC) as first-line therapy …
[HTML][HTML] Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study
V Alanen, S Iivanainen, M Arffman, JP Koivunen - ESMO open, 2020 - Elsevier
Background With the first and second-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI …
tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI …